COVID-19 therapies: do we see substantial progress?

The appearance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its spread all over the world is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has recently resulted in almost 400 million confirmed cases and 6 million deaths, not to mention unknown long-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Matusewicz, Lucyna, Golec, Marlena, Czogalla, Aleksander, Kuliczkowski, Kazimierz, Konka, Adam, Zembala-John, Joanna, Sikorski, Aleksander F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152818/
https://www.ncbi.nlm.nih.gov/pubmed/35641916
http://dx.doi.org/10.1186/s11658-022-00341-9
_version_ 1784717717267283968
author Matusewicz, Lucyna
Golec, Marlena
Czogalla, Aleksander
Kuliczkowski, Kazimierz
Konka, Adam
Zembala-John, Joanna
Sikorski, Aleksander F.
author_facet Matusewicz, Lucyna
Golec, Marlena
Czogalla, Aleksander
Kuliczkowski, Kazimierz
Konka, Adam
Zembala-John, Joanna
Sikorski, Aleksander F.
author_sort Matusewicz, Lucyna
collection PubMed
description The appearance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its spread all over the world is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has recently resulted in almost 400 million confirmed cases and 6 million deaths, not to mention unknown long-term or persistent side effects in convalescent individuals. In this short review, we discuss approaches to treat COVID-19 that are based on current knowledge of the mechanisms of viral cell receptor recognition, virus–host membrane fusion, and inhibition of viral RNA and viral assembly. Despite enormous progress in antiviral therapy and prevention, new effective therapies are still in great demand.
format Online
Article
Text
id pubmed-9152818
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91528182022-06-02 COVID-19 therapies: do we see substantial progress? Matusewicz, Lucyna Golec, Marlena Czogalla, Aleksander Kuliczkowski, Kazimierz Konka, Adam Zembala-John, Joanna Sikorski, Aleksander F. Cell Mol Biol Lett Review Letter The appearance of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its spread all over the world is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has recently resulted in almost 400 million confirmed cases and 6 million deaths, not to mention unknown long-term or persistent side effects in convalescent individuals. In this short review, we discuss approaches to treat COVID-19 that are based on current knowledge of the mechanisms of viral cell receptor recognition, virus–host membrane fusion, and inhibition of viral RNA and viral assembly. Despite enormous progress in antiviral therapy and prevention, new effective therapies are still in great demand. BioMed Central 2022-05-31 /pmc/articles/PMC9152818/ /pubmed/35641916 http://dx.doi.org/10.1186/s11658-022-00341-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Letter
Matusewicz, Lucyna
Golec, Marlena
Czogalla, Aleksander
Kuliczkowski, Kazimierz
Konka, Adam
Zembala-John, Joanna
Sikorski, Aleksander F.
COVID-19 therapies: do we see substantial progress?
title COVID-19 therapies: do we see substantial progress?
title_full COVID-19 therapies: do we see substantial progress?
title_fullStr COVID-19 therapies: do we see substantial progress?
title_full_unstemmed COVID-19 therapies: do we see substantial progress?
title_short COVID-19 therapies: do we see substantial progress?
title_sort covid-19 therapies: do we see substantial progress?
topic Review Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152818/
https://www.ncbi.nlm.nih.gov/pubmed/35641916
http://dx.doi.org/10.1186/s11658-022-00341-9
work_keys_str_mv AT matusewiczlucyna covid19therapiesdoweseesubstantialprogress
AT golecmarlena covid19therapiesdoweseesubstantialprogress
AT czogallaaleksander covid19therapiesdoweseesubstantialprogress
AT kuliczkowskikazimierz covid19therapiesdoweseesubstantialprogress
AT konkaadam covid19therapiesdoweseesubstantialprogress
AT zembalajohnjoanna covid19therapiesdoweseesubstantialprogress
AT sikorskialeksanderf covid19therapiesdoweseesubstantialprogress

Ejemplares similares